Skip to main content
JADPRO Live 2025 Main banner
Icon Legend
Presentation Icons
CE Credit Available
CE Credit Available
Poster Presentation
Poster Presentation
Pharmacology Credit Available
Pharmacology Credit Available
Surgical Oncology
Surgical Oncology
Radiation Oncology
Radiation Oncology
Ticketed Session - Additional Fee
Ticketed Session - Additional Fee
Capturing for On Demand
Capturing for On Demand
Ticketed Event - Included w. Registration
Ticketed Event - Included w. Registration

Full Schedule

  1. Home
  2. Full Schedule

Full Schedule

  • Saturday, October 25, 2025
  • 6:30 AM - 5:30 PM ET
    Conference Registration
  • 6:45 AM - 5:00 PM ET
    Exhibitor Registration & Lead Retrieval
  • 7:00 AM - 8:15 AM ET
    Breakfast Activity: Non-CE Satellite Symposium: A Fixed- Duration Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma
    Genentech
  • 7:00 AM - 8:15 AM ET
    Breakfast Activity: Non-CE Satellite Symposium: A Treatment Option for certain patients with Hepatocellular Carcinoma
    Bristol Myers Squibb
  • 7:00 AM - 8:15 AM ET
    Breakfast Activity: Non-CE Satellite Symposium: Treatment Options for Appropriate Patients With Certain Types of Advanced Gynecologic Cancers
    Merck & Co., Inc.
  • 7:00 AM - 8:15 AM ET
    Exhibit Hall Open &
    Continental Breakfast
  • 7:00 AM - 8:15 AM ET
    Professional Profile Pavilion
  • 7:00 AM - 8:15 PM ET
    Breakfast Activity: Non-CE Satellite Symposium: AYVAKIT, The only approved treatment for Indolent Systemic Mastocytosis and Advanced Systemic Mastocytosis
    Blueprint Medicines
  • 8:20 AM - 8:30 AM ET
    Opening Remarks & APSHO FAPO Recognition Presentation
  • 8:30 AM - 8:40 AM ET
    The Annual Mary Pazdur Award Presentation
  • 8:45 AM - 9:15 AM ET
    The Mary Pazdur Award Recipient Lecture
  • 9:25 AM - 10:25 AM ET
    Interpreting Post-Therapeutic Diagnostic Studies
  • 9:25 AM - 10:25 AM ET
    Rebuilding Form and Function: Innovations in Reconstructive Care for the Patient With Cancer
  • 9:25 AM - 10:25 AM ET
    Therapeutic Advances in Metastatic Melanoma: TILs, ImmTACs, and Targeted Therapies
  • 9:45 AM - 4:30 PM ET
    Braindate
  • 10:30 AM - 11:30 AM ET
    Exhibit Hall Open &
    Refreshment Break
  • 10:30 AM - 11:30 AM ET
    Moderated Posters
  • 10:30 AM - 11:30 AM ET
    Professional Profile Pavilion
  • 10:35 AM - 11:05 AM ET
    Exhibit Hall Presentation Theater: EMERALD Study Update: Safety and Efficacy Data in Patients with ER+/HER2-, ESR1-mutated Metastatic Breast Cancer, including Subgroup Analyses
    Stemline, a Menarini Group Company
  • 10:35 AM - 11:05 AM ET
    Exhibit Hall Presentation: The Future of Endocrine Therapy Management: Harnessing Genomics for Better Outcomes
    Agendia
  • 10:35 AM - 11:20 AM ET
    Exhibit Hall Presentation: From Evidence to Action: A Case-Based Approach to Collaborative BCL2-Inhibitor Management in AML
    AbbVie
  • 11:00 AM - 11:30 AM ET
    APSHO Meet & Greet
    Professional & Leadership Development (PD&L) Committee
  • 11:40 AM - 12:40 PM ET
    Advances and Controversies in the Surgical Management of Colorectal Liver Metastases
  • 11:40 AM - 12:40 PM ET
    Evidence-Based Exercise and Diet Strategies Across the Continuum of Cancer Care
  • 11:40 AM - 12:40 PM ET
    Latest Clinical Evidence in Extensive Stage Small Cell Lung Cancer Treatment
  • 12:45 PM - 2:00 PM ET
    Exhibit Hall Open &
    Lunch
  • 12:45 PM - 2:00 PM ET
    Lunch Activity/Non-CE Satellite Symposium: Get the Facts on RYBREVANT™-Based Regimens in EGFR+* Locally Advanced or mNSCLC
    Johnson & Johnson
  • 12:45 PM - 2:00 PM ET
    Lunch Activity/Non-CE Satellite Symposium: Make a Change in cGVHD Treatment Strategy and Provide Rapid, Durable Responses
    Incyte Corporation
  • 12:45 PM - 2:00 PM ET
    Lunch Activity: Non-CE Satellite Symposium: An Exelixis Clinical Presentation on CABOMETYX® (cabozantinib)
    Exelixis
  • 12:45 PM - 2:00 PM ET
    Lunch Activity: Non-CE Satellite Symposium: Biomarker-Directed Treatment Options for ALK-Positive or BRAF V600E–Mutated Metastatic NSCLC
    Pfizer, Inc.
  • 12:45 PM - 2:00 PM ET
    Lunch Activity: Non-CE Satellite Symposium: Myelofibrosis and Strategies for Disease Management: Key Considerations for Patient Care
    GSK
  • 12:45 PM - 2:00 PM ET
    Professional Profile Pavilion
  • 1:00 PM - 1:30 PM ET
    APSHO Meet & Greet
    Membership Committee
  • 1:30 PM - 2:00 PM ET
    APSHO Meet & Greet
    Education Committee
  • 2:05 PM - 2:50 PM ET
    Management of Myelodysplastic Syndromes: Emerging Therapies and Evidence-Based Practice
  • 2:05 PM - 2:50 PM ET
    Targeting More Than Tumors: Applying Pharmacogenomics to Oncology Practice
  • 2:05 PM - 2:50 PM ET
    The Role of Radiation Therapy for Oligometastatic Lung Cancer
  • 3:00 PM - 3:30 PM ET
    APSHO Meet & Greet
    Research & Quality Improvement (RQI) Committee
  • 3:00 PM - 4:15 PM ET
    Exhibit Hall Open &
    Refreshment Break
  • 3:00 PM - 4:15 PM ET
    Professional Profile Pavilion
  • 3:05 PM - 3:35 PM ET
    Exhibit Hall Presentation Theater: Living with Advanced NSCLC*: A Patient’s Treatment Journey
    Regeneron Pharmaceuticals
  • 3:05 PM - 3:35 PM ET
    Exhibit Hall Presentation: Peer insights to help identify and manage candidates for treatment with a CDK4/6 inhibitor.© Lilly USA, LLC 2025. All rights reserved.
  • 3:05 PM - 3:45 PM ET
    Exhibit Hall Presentation: Exploring BCL-2i-based Time-Limited Regimens Throughout the CLL Treatment Journey
    AbbVie
  • 3:30 PM - 4:00 PM ET
    APSHO Meet & Greet:
    Radiation Oncology Committee
  • 4:25 PM - 5:25 PM ET
    Beyond the Usual Suspects: Differentiating and Managing Complex Soft-Tissue Tumors
  • 4:25 PM - 5:25 PM ET
    Elevating Your Voice: Empowering Advanced Practitioners in the Insurance Peer-to-Peer Process
  • 4:25 PM - 5:40 PM ET
    New-to-Oncology Roundtables
  • 5:00 PM - 7:30 PM ET
    Independent CE Satellite Symposium: Advancing Care in Genitourinary Cancers: Integrating Targeted Therapies for Metastatic Urothelial Carcinoma and Advanced Prostate Cancer
  • 7:00 PM - 8:30 PM ET
    Independent CE Dinner Satellite Symposium: Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic Disease